Robert Millham
Impact in
- Immunology top 5%
- Immunotherapy and Immune Responses
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Papers in
- Oncology 7
- Colorectal Cancer Treatments and Studies 3
- Cancer Treatment and Pharmacology 2
- HER2/EGFR in Cancer Research 2
-
- PI3K/AKT/mTOR signaling in cancer 5
- Co-authors
- Amarnath Sharma (3 shared papers)Jesús Gómez-Navarro (3 shared papers)Antoni Ribas (3 shared papers)Gabriel Lopez‐Berestein (1 shared paper)C. A. Bulanhagui (1 shared paper)Begoña Comı́n-Anduix (1 shared paper)John A. Glaspy (1 shared paper)Charla A. Parker (1 shared paper)
- Journals
- Journal of Clinical Oncology (5 papers)Clinical Cancer Research (4 papers)Molecular Cancer Therapeutics (2 papers)Investigational New Drugs (1 paper)European Journal of Cancer (1 paper)
- Partner nations
- United StatesSpainItaly
In The Last Decade
Robert Millham
20 papers receiving 1.6k citations
Robert Millham's Hit Papers
Peers
Comparison fields: 5 of 108
- Immunology 562
- Oncology 656
- Pulmonary and Respiratory Medicine 291
- Molecular Biology 561
- Genetics 72
Countries citing papers authored by Robert Millham
This map shows the geographic impact of Robert Millham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Millham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Millham more than expected).
Fields of papers citing papers by Robert Millham
This network shows the impact of papers produced by Robert Millham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Millham. The network helps show where Robert Millham may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Millham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement Hit paper breakdown → | 2006 | 512 |
| 2 | 2005 | 439 | |
| 3 | 2011 | 153 | |
| 4 | 2007 | 136 | |
| 5 | 2015 | 97 | |
| 6 | 2014 | 66 | |
| 7 | 2007 | 56 | |
| 8 | 2008 | 53 | |
| 9 | 2010 | 35 | |
| 10 | 2016 | 31 | |
| 11 | 2010 | 20 | |
| 12 | 2011 | 13 | |
| 13 | 2012 | 10 | |
| 14 | 2012 | 5 | |
| 15 | 2010 | 5 | |
| 16 | 2011 | 4 | |
| 17 | 2006 | 3 | |
| 18 | 2012 | 3 | |
| 19 | 2010 | 3 | |
| 20 | 2010 | 3 |
About Robert Millham
Robert Millham is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Genetics, having authored 20 papers that have together received 1.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (5 papers), Lung Cancer Treatments and Mutations (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Estrogen and related hormone effects (2 papers), Immunotherapy and Immune Responses (2 papers), Cancer Treatment and Pharmacology (2 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Immunology (562 citations), Oncology (656 citations), Pulmonary and Respiratory Medicine (291 citations), Molecular Biology (561 citations) and Genetics (72 citations). Robert Millham has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Amarnath Sharma, Jesús Gómez-Navarro, Antoni Ribas, Gabriel Lopez‐Berestein, C. A. Bulanhagui, Begoña Comı́n-Anduix, John A. Glaspy, Charla A. Parker, Elisabeth Seja and Luis H. Camacho. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Molecular Cancer Therapeutics, Investigational New Drugs and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.